Page last updated: 2024-12-06

aloxistatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aloxistatin: a membrane-permeable cysteine protease inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65663
CHEMBL ID63440
CHEBI ID101381
SCHEMBL ID483320
MeSH IDM0322622

Synonyms (88)

Synonym
CBIOL_001881
(2s,3s)-3-[(s)-3-methyl-1-(3-methyl-butylcarbamoyl)-butylcarbamoyl]-oxirane-2-carboxylic acid ethyl ester
3-[3-methyl-1-(3-methyl-butylcarbamoyl)-butylcarbamoyl]-oxirane-2-carboxylic acid ethyl ester
bdbm50052693
(2s,3s)-ethyl 3-(((s)-1-(isopentylamino)-4-methyl-1-oxopentan-2-yl)carbamoyl)oxirane-2-carboxylate
88321-09-9
aloxistatin
smr000058552
loxistatin
MLS000028372 ,
e-64-d
ethyl (+)-(2s,3s)-2,3-epoxy-n-((s)-1-(isopentylcarbamoyl)-3-methylbutyl)succinamate
e 64d
ccris 1934
ep 453
oxiranecarboxylic acid, 3-(((3-methyl-1-(((3-methylbutyl)amino)carbonyl)butyl)amino)carbonyl)-, ethyl ester, (2s-(2-alpha,3-beta(r*)))-
est (pharmaceutical)
oxiranecarboxylic acid, 3-((((1s)-3-methyl-1-(((3-methylbutyl)amino)carbonyl)butyl)amino)carbonyl)-, ethyl ester, (2s,3s)-
aloxistatinum [latin]
aloxistatine [french]
e 64c ethyl ester
brn 5354546
nsc 694281
aloxistatin [inn]
aloxistatina [spanish]
BIO1_000167
BIO1_000656
BIO1_001145
EST ,
e-64d, protease inhibitor
nsc694281
nsc-694281
e-64d
(2s,3s)-trans-epoxysuccinyl-l-leucylamido-3-methylbutane ethyl ester
CHEMBL63440 ,
ethyl (2s,3s)-3-[[(2s)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
aloxistatinum
e64d
ethyl (2s,3s)-3-({(2s)-4-methyl-1-[(3-methylbutyl)amino]-1-oxopentan-2-yl}carbamoyl)oxirane-2-carboxylate
aloxistatine
aloxistatina
CHEBI:101381
HMS2236F06
l5w337aour ,
unii-l5w337aour
S7393
CCG-207846
MLS006010826
loxistatin [jan]
SCHEMBL483320
(2s,3s)-3-[[[(1s)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-2-oxiranecarboxylic acid ethyl ester
SRVFFFJZQVENJC-IHRRRGAJSA-N
3-[[[(1s)-3-methyl-1[[(3s-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-2s-oxiranecarboxylic acid, ethyl ester
FD21942
AKOS024458215
HMS3403C21
OPERA_ID_506
mfcd00132883
Q27177634
(2s,3s)-trans-epoxysuccinyl-l-leucylamido-3-methylbutane ethyl ester est
EX-A860
sr-01000759197
SR-01000759197-2
e64c ethyl ester
estat
trans-ethyl (+)-(2s,3s)-2,3-epoxy-n-((s)-1-(isopentylcarbamoyl)-3-methylbutyl)succinamate
ethyl (2s,3s)-3-[[(1s)-1-(isopentylcarbamoyl)-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate
CS-5996
HY-100229
NCGC00167328-03
(2s,3s)-3-[[[(1s)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]-butyl]amino]carbonyl]-2-oxiranecarboxylic acid ethyl ester
e-64d(aloxistatin)
est - cas 88321-09-9
e-64d(aloxistatin,loxistatin pound(c)
ethyl (2s,3s)-3-(((s)-1-(isopentylamino)-4-methyl-1-oxopentan-2-yl)carbamoyl)oxirane-2-carboxylate
BRD-K91188791-001-12-6
BRD-K91188791-001-18-3
A13259
HMS3886N13
C76913
DTXSID00904150
AS-55817
gtpl10714
compound 2b [pmid: 8765519]
ep453
E1337
e-64d [for biochemical research]
AC-35497

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
cathepsin B inhibitorA cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
L-leucine derivativeA proteinogenic amino acid derivative resulting from reaction of L-leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-leucine by a heteroatom.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ClpPBacillus subtilisPotency35.48131.995322.673039.8107AID651965
PPM1D proteinHomo sapiens (human)Potency0.11710.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency18.15270.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
gemininHomo sapiens (human)Potency12.58930.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency0.11710.00339.158239.8107AID1347411
Guanine nucleotide-binding protein GHomo sapiens (human)Potency22.38721.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
calpain II, partialSus scrofa (pig)IC50 (µMol)1.77421.77424.93387.7087AID1420
PapainCarica papaya (papaya)Ki52.00002.40003.74005.0800AID155404
Calpain-1 catalytic subunitHomo sapiens (human)IC50 (µMol)23.42000.00021.059210.0000AID1712997; AID46338; AID46342
Procathepsin LHomo sapiens (human)IC50 (µMol)2.41000.00021.66619.5100AID1712999
Cathepsin BHomo sapiens (human)IC50 (µMol)14.39000.00021.845310.0000AID1712998
Cathepsin GHomo sapiens (human)IC50 (µMol)1.10000.01372.42247.4130AID360119
Neutrophil elastaseMus musculus (house mouse)IC50 (µMol)10.00000.14540.14540.1454AID360128
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
positive regulation of cell population proliferationCalpain-1 catalytic subunitHomo sapiens (human)
regulation of macroautophagyCalpain-1 catalytic subunitHomo sapiens (human)
receptor catabolic processCalpain-1 catalytic subunitHomo sapiens (human)
regulation of catalytic activityCalpain-1 catalytic subunitHomo sapiens (human)
mammary gland involutionCalpain-1 catalytic subunitHomo sapiens (human)
self proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
regulation of NMDA receptor activityCalpain-1 catalytic subunitHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
angiotensin maturationCathepsin GHomo sapiens (human)
monocyte chemotaxisCathepsin GHomo sapiens (human)
protein phosphorylationCathepsin GHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
immune responseCathepsin GHomo sapiens (human)
protein processingCathepsin GHomo sapiens (human)
cytokine-mediated signaling pathwayCathepsin GHomo sapiens (human)
protein metabolic processCathepsin GHomo sapiens (human)
antibacterial humoral responseCathepsin GHomo sapiens (human)
extracellular matrix disassemblyCathepsin GHomo sapiens (human)
platelet activationCathepsin GHomo sapiens (human)
purinergic nucleotide receptor signaling pathwayCathepsin GHomo sapiens (human)
neutrophil activationCathepsin GHomo sapiens (human)
positive regulation of immune responseCathepsin GHomo sapiens (human)
defense response to Gram-negative bacteriumCathepsin GHomo sapiens (human)
defense response to Gram-positive bacteriumCathepsin GHomo sapiens (human)
defense response to fungusCathepsin GHomo sapiens (human)
negative regulation of T cell activationCathepsin GHomo sapiens (human)
neutrophil-mediated killing of gram-positive bacteriumCathepsin GHomo sapiens (human)
cellular response to lipopolysaccharideCathepsin GHomo sapiens (human)
biofilm matrix disassemblyCathepsin GHomo sapiens (human)
positive regulation of platelet aggregationCathepsin GHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
calcium ion bindingCalpain-1 catalytic subunitHomo sapiens (human)
protein bindingCalpain-1 catalytic subunitHomo sapiens (human)
peptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
serine-type endopeptidase activityCathepsin GHomo sapiens (human)
protein bindingCathepsin GHomo sapiens (human)
heparin bindingCathepsin GHomo sapiens (human)
peptidase activityCathepsin GHomo sapiens (human)
serine-type peptidase activityCathepsin GHomo sapiens (human)
receptor ligand activityCathepsin GHomo sapiens (human)
caspase bindingCathepsin GHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cornified envelopeCalpain-1 catalytic subunitHomo sapiens (human)
extracellular regionCalpain-1 catalytic subunitHomo sapiens (human)
mitochondrionCalpain-1 catalytic subunitHomo sapiens (human)
lysosomeCalpain-1 catalytic subunitHomo sapiens (human)
cytosolCalpain-1 catalytic subunitHomo sapiens (human)
plasma membraneCalpain-1 catalytic subunitHomo sapiens (human)
focal adhesionCalpain-1 catalytic subunitHomo sapiens (human)
membraneCalpain-1 catalytic subunitHomo sapiens (human)
extracellular exosomeCalpain-1 catalytic subunitHomo sapiens (human)
calpain complexCalpain-1 catalytic subunitHomo sapiens (human)
ficolin-1-rich granule lumenCalpain-1 catalytic subunitHomo sapiens (human)
cytoplasmCalpain-1 catalytic subunitHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular regionCathepsin GHomo sapiens (human)
extracellular spaceCathepsin GHomo sapiens (human)
nucleusCathepsin GHomo sapiens (human)
lysosomeCathepsin GHomo sapiens (human)
cytosolCathepsin GHomo sapiens (human)
plasma membraneCathepsin GHomo sapiens (human)
cytoplasmic stress granuleCathepsin GHomo sapiens (human)
membraneCathepsin GHomo sapiens (human)
secretory granuleCathepsin GHomo sapiens (human)
azurophil granule lumenCathepsin GHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular exosomeCathepsin GHomo sapiens (human)
cytoplasmCathepsin GHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin GHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID562322Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 5 gametocyte per 1000 RBCs at 100 uM after 5 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID46340The calpain inhibitory activity(I 50) was measured as ability to enter the platelet and inhibit calpain in the intact cells(assay 3); (+)indicates substantial inhibition by 5-44 uM1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Ester and amide derivatives of E64c as inhibitors of platelet calpains.
AID562319Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 4 gametocytes per 1000 RBCs at 100 uM after 2 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID726632Sensitization of human RPMI8226 cells to Carfilzomib assessed as cell viability at 10 uM after 48 hrs2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.
AID283318Inhibition of Pfs230 processing after 1 hrs in Plasmodium falciparum 3D7 at 100 uM in emergence medium2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID562320Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 3 gametocyte per 1000 RBCs at 100 uM after 5 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID283312Inhibition at day 7 of Plasmodium falciparum 3D7 oocyst production in human serum at 100 uM for 1 hrs prior to feeding Anopheles stephensi SxK Nij 2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID155416Kinetic constant First order rate of inactivation (K3) for the inhibition of papain conducted in 0.1 M phosphate, pH 6.8, at 30 degree C1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors.
AID283308Inhibition of oocyst production after 7 days in Anopheles stephensi SxK Nij fed human serum infected with Plasmodium falciparum NF54 stage V gametocyte at 100 uM for 1 hr2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324579Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID155404Kinetic constant Apparent binding constant (Ki`) for the inhibition of papain conducted in 0.1 M phosphate, pH 6.8, at 30 degree C1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors.
AID1713006Inhibition of mu-calpain (unknown origin) expressed in HEK293T cells assessed as reduction in p35 cleavage at 100 uM using p35 as substrate measured after 210 mins by fluorescence microplate reader assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID1713010Neuroprotective activity in human SH-SY5Y cells assessed as reduction in GOx-induced PARP cleavage at 20 uM pretreated with GOx for 4 hrs followed by compound treatment by Western blot analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID46338The ability of compound to inhibit calpain in a preparation of lysed platelets was measured with a caseinolytic assay(assay 1)1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Ester and amide derivatives of E64c as inhibitors of platelet calpains.
AID360119Blockade of cathepsin G processing in human U937 cells by densitometry2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID562318Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 3 gametocytes per 1000 RBCs at 100 uM after 2 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID283314Inhibition of gametogenesis after 1 hrs in Plasmodium falciparum 3D7 at 100 uM in emergence medium 2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324392Induction of light chain 3-GFP level in human H4 cells at 7.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1712997Inhibition of human erythrocytes mu-calpain using Pep1 as substrate incubated for 30 mins under shaking condition in presence of CaCl2 by fluorescence assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID1713003Inhibition of mu-calpain (unknown origin) expressed in SH-SY5Y cells assessed as reduction in p35 cleavage at 100 uM using p35 as substrate measured after 210 mins by fluorescence microplate reader assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID360128Inhibition of neutrophil elastase activation in beta-estradiol differentiated mouse EcoM-G cells after 24 hrs2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1708724Inhibition KCN-induced elastase like activity in human U-937 cells using substrate MAAPV2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID360129Inhibition of cathepsin G activation in beta-estradiol differentiated mouse EcoM-G cells after 24 hrs2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID324581Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324444Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 7.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID562316Antimicrobial activity against asexual stage of Plasmodium falciparum 3D7 assessed as reduction in parasite count at 100 uM after 24 hrs by Giemsa staining2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID46342The calpain inhibitory activity(I 50) was measured as ability to enter the platelet to inhibit calpain after cell lysis(assay 2)1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Ester and amide derivatives of E64c as inhibitors of platelet calpains.
AID324548Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 7.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1712998Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID324580Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID283311Inhibition of oocyst production after 7 days in Anopheles stephensi SxK Nij fed human serum infected with Plasmodium falciparum 3D7 stage V gametocyte at 10 uM for 1 hr2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID360120Blockade of neutrophil elastase processing in human U937 cells after 7 days by fluorogenic substrate cleavage assay2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID1712999Inhibition of cathepsin L (unknown origin) using Z-FR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID283313Gametocyte morphology as exflagellation after 15-30 min in Plasmodium falciparum 3D7 at 100 uM for 1hr in emergence medium2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID360130Inhibition of proteinase-3 activation in beta-estradiol differentiated mouse EcoM-G cells after 24 hrs2007The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
AID726630Potentiation of NC-022-induced sensitization of human RPMI8226 cells to Carfilzomib assessed as cell viability at 10 uM after 48 hrs2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.
AID562317Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 2 gametocytes per 1000 RBCs at 100 uM after 2 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID283310Inhibition of oocyst production after 7 days in Anopheles stephensi SxK Nij fed human serum infected with Plasmodium falciparum NF54 stage V gametocyte at 100 uM for 15 min2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID283309Inhibition of oocyst production after 7 days in Anopheles stephensi SxK Nij fed human serum infected with Plasmodium falciparum NF54 stage V gametocyte at 100 uM for 30 min2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
AID279769Inhibition of Toxoplasma gondii 2F1 invasion in HFF cells assessed as beta-galactosidase activity at 10 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion.
AID562321Antimicrobial activity against Plasmodium falciparum 3D7 assessed as stage 4 gametocyte per 1000 RBCs at 100 uM after 5 days by Giemsa staining relative to control2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
AID324496Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 7.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID155420Kinetic constant Apparent second order rate of inactivation (Ki) for the inhibition of papain conducted in 0.1 M phosphate, pH 6.8, at 30 degree C1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (148)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (6.76)18.7374
1990's32 (21.62)18.2507
2000's62 (41.89)29.6817
2010's37 (25.00)24.3611
2020's7 (4.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.68 (24.57)
Research Supply Index5.04 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.65%)5.53%
Reviews1 (0.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other151 (98.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]